Stockscreener 앱 받기
1.70
6.92%
0.11
시장 영업 전:
1.72
0.02
+1.18%
전일 마감가:
$1.59
열려 있는:
$1.61
하루 거래량:
1.25M
Relative Volume:
0.94
시가총액:
$117.59M
수익:
-
순이익/손실:
$-77.22M
주가수익비율:
-0.9696
EPS:
-1.7533
순현금흐름:
$-77.27M
1주 성능:
+23.19%
1개월 성능:
+9.68%
6개월 성능:
-67.74%
1년 성능:
+20.57%
1일 변동 폭
$1.595
$1.78
1주일 범위
$1.35
$1.78
52주 변동 폭
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
명칭
Pepgen Inc
전화
703-456-8000
주소
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.70 | 105.83M | 0 | -77.22M | -77.27M | -1.7533 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-09 | 개시 | Guggenheim | Buy |
| 2024-12-16 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-07-31 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-21 | 개시 | H.C. Wainwright | Buy |
Pepgen Inc 주식(PEPG)의 최신 뉴스
PEPG Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Continued R&D Progress - newsline.com
Why PEPG, SGMO, PHR Are Among Top Premarket Losers Today - Stocktwits
PEPG Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Lack of RevenueEarnings Momentum Score - The League of Women Voters of Texas
PEPG Q1 2026 Earnings: Narrower Loss Per Share Beats Estimates as Biotech Advances PipelineEarnings Surprise Stocks - newsline.com
PEPG Q1 2026 Earnings: Narrower-than-Expected Loss Drives Stock HigherLow Estimate Range - newsline.com
PepGen Inc. (PEPG) Q1 2026 Earnings: Narrowed Loss Surprises Analysts, Shares Edge HigherReturn On Capital - newsline.com
PepGen Inc. (PEPG) Q1 2026 Earnings: Narrower-than-Expected Loss Drives Cautious OptimismGuidance Revision Trend - newsline.com
PepGen Inc. (PEPG) Rallies 4.23% as Biotech Stock Tests Key Resistance at $1.55Bollinger Expansion - newsline.com
PepGen showcases research advancements on DM1 at industry conference - Traders Union
PepGen attends ANN and AOMC Congress in Perth to engage neuromuscular research community - Traders Union
PepGen's cash reserves offer comfort for now, but rising cash burn and no revenue spark concerns. Investors are urged to remain cautious due to funding needs and dilution risk. - Moomoo
PepGen (PEPG) upgraded to buy: Here's what you should know - MSN
PepGen Inc. (PEPG): Stock Holds Steady at $1.50 as Key Resistance LoomsNAAIM Exposure - newsline.com
PepGen Inc. (PEPG) Nears Support as Stock Slips SlightlyEarnings Sentiment - The Legal Advocate
PepGen Inc. (PEPG) Slips to $1.5 as Stock Navigates Key Support ZoneBPI Bear Correction - The Legal Advocate
PEPG Q1 2026 Earnings: Narrower-than-Expected Loss Signals Progress in Neuromuscular PipelineCost Structure Review - The Legal Advocate
PepGen (NASDAQ: PEPG) CTO executes mandatory sell-to-cover RSU shares - Stock Titan
PepGen Inc. (PEPG) Slips 1.95% as Stock Tests Key Support LevelsSign of Weakness - Newser
PepGen launches outreach campaign with DM1 stakeholders in Canada - Traders Union
[EFFECT] PepGen Inc. SEC Filing - Stock Titan
PEPG Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Risk Report - newsline.com
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program - BioSpace
PepGen’s PGN-EDODM1 Shows Promising Safety and Efficacy in Myotonic Dystrophy Type 1 Clinical Trials – FREEDOM2 Study Update - Minichart
H.C. Wainwright reiterates PepGen stock rating on data outlook By Investing.com - Investing.com South Africa
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting - PharmiWeb.com
PepGen unveils new PGN-EDODM1 clinical data at IDMC-15 - Traders Union
PepGen Highlights DM1 Program Progress in Updated Presentation - TipRanks
H.C. Wainwright reiterates PepGen stock rating on data outlook - Investing.com
PepGen updates corporate presentation, highlights FREEDOM2 milestones and PGN-EDODM1 data - TradingView
PepGen (NASDAQ: PEPG) details DM1 trial data and cash runway outlook - Stock Titan
PepGen (PEPG) loses 14.3% in 4 weeks, here's why a trend reversal may be around the corner - MSN
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance UK
PepGen files to offer up to $400 mln in securities from time to time - marketscreener.com
PepGen Files To Offer Up To $400 Mln In Securities From Time To Time - TradingView
According to documents submitted to the SEC, biotechnology company PepGen Inc. has signed a new sales agreement, which will completely replace the company's previous sales arrangement. - Bitget
PepGen Files $400 Million Mixed Shelf - Moomoo
PepGen (NASDAQ: PEPG) ups capital flexibility with $400M shelf and $100M ATM - Stock Titan
PepGen Cuts Net Losses to 17.8 Million Dollars in First Quarter - HarianBasis.co
Is PepGen (PEPG) One of the Best NASDAQ Stocks Under $5 to Buy Right Now? - Insider Monkey
Why is PepGen stock sinking Tuesday? - MSN
Viking Global reports 3.48M shares in PepGen (NASDAQ: PEPG) - Stock Titan
[SCHEDULE 13G/A] PepGen Inc. Amended Passive Investment Disclosure - Stock Titan
TradingKey - TradingKey
Wedbush Maintains PepGen(PEPG.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
PepGen Inc. Stock 12‑Month Price Target Cut to $10, Implies 495% Upside - TradingView
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Wedbush Trims Price Target on PepGen to $4 From $5, Maintains Outperform Rating - marketscreener.com
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights - BioSpace
Pepgen Inc (PEPG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Pepgen Inc 주식 (PEPG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STRECK PAUL | EVP, Head of R&D |
Mar 04 '26 |
Sale |
6.23 |
1,879 |
11,709 |
76,226 |
| Donnelly Noel | Chief Financial Officer |
Mar 04 '26 |
Sale |
6.23 |
2,084 |
12,988 |
111,603 |
| McArthur James G | President and CEO |
Mar 04 '26 |
Sale |
6.23 |
5,275 |
32,876 |
296,326 |
| Oxford Science Enterprises plc | Former 10% Owner |
Sep 30 '25 |
Buy |
3.20 |
200,000 |
640,000 |
4,955,388 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Sep 26 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
18,554,273 |
2.60%
0.94%
자본화:
|
볼륨(24시간):